Madrigal Pharmaceuticals Inc
Closed
SectorHealthcare
506.91 1.81
Overview
Share price change
24h
Min
485.19
Max
508.57
Income | -36M -94M |
|---|---|
Sales | -9.7M 311M |
EPS | -1.38 |
Profit margin | -30.318 |
Employees | 915 |
EBITDA | -36M -86M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +29.8% upside |
Next Earnings | 4 sie 2026 |
|---|
Market Cap | -481M 11B |
|---|---|
Previous open | 505.1 |
Previous close | 506.91 |
News Sentiment
By Acuity
51%
49%
247 / 342 Ranking in Healthcare
Madrigal Pharmaceuticals Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
